Sevelamer Improves Steatohepatitis, Inhibits Liver and Intestinal Farnesoid X Receptor (FXR), and Reverses Innate Immune Dysregulation in a Mouse Model of Non-alcoholic Fatty Liver Disease

Journal of Biological Chemistry

Volumn 291, Issue 44, 2016, Pages 23058-23067

  McGettigan, Brett M ^a   McMahan, Rachel H ^a   Luo, Yuhuan ^a   Wang, Xiaoxin X ^a   Orlicky, David J ^b   Porsche, Cara ^a   Levi, Moshe ^a   Rosen, Hugo R ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BODY FLUIDS; ENZYME INHIBITION; GENE EXPRESSION; GENES; LIVER; MACROPHAGES; MAMMALS; PATHOLOGY; SIGNALING;

BILE ACID SEQUESTRANTS; DISEASE SEVERITY; FARNESOID X RECEPTORS; INSULIN SENSITIVITY; LIVER STEATOSIS; NON-ALCOHOLIC FATTY LIVER DISEASE; SIGNALING PATHWAYS; SYNTHETIC POLYMERS;

DISEASES;

ALPHA SMOOTH MUSCLE ACTIN; CHOLESTEROL 7ALPHA MONOOXYGENASE; PROTEIN TYROSINE PHOSPHATASE SHP; SEVELAMER; ANTIINFLAMMATORY AGENT; CELL RECEPTOR; FARNESOID X-ACTIVATED RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ARTICLE; CELL POPULATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; FXR GENE; GENE; GENE EXPRESSION; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; MACROPHAGE; MONOCYTE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; TREATMENT OUTCOME; ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; GENETICS; HUMAN; IMMUNOLOGY; INTESTINE; LIVER; MALE; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; SIGNAL TRANSDUCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNITY, INNATE; INTESTINES; LIVER; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; NON-ALCOHOLIC FATTY LIVER DISEASE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SEVELAMER; SIGNAL TRANSDUCTION;

EID: 84994045430     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M116.731042     Document Type: Article

References (45)

1. Vernon, G., Baranova, A., and Younossi, Z. M. (2011) Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment. Pharmacol. Ther. 34, 274-285
2. Levene, A. P., and Goldin, R. D. (2012) The epidemiology, pathogenesis and histopathology of fatty liver disease. Histopathology 61, 141-152
3. Wree, A., Broderick, L., Canbay, A., Hoffman, H. M., and Feldstein, A. E. (2013) From NAFLD to NASH to cirrhosis-new insights into disease mechanisms. Nat. Rev. Gastroenterol. Hepatol. 10, 627-636
4. Hossain, N., Afendy, A., Stepanova, M., Nader, F., Srishord, M., Rafiq, N., Goodman, Z., and Younossi, Z. (2009) Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 7, 1224-1229, 1229.e1-2
5. Ratziu, V., Giral, P., Charlotte, F., Bruckert, E., Thibault, V., Theodorou, I., Khalil, L., Turpin, G., Opolon, P., and Poynard, T. (2000) Liver fibrosis in overweight patients. Gastroenterology 118, 1117-1123
6. Argo, C. K., Northup, P. G., Al-Osaimi, A. M., and Caldwell, S. H. (2009) Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J. Hepatol. 51, 371-379
7. Charlton, M. R., Burns, J. M., Pedersen, R. A., Watt, K. D., Heimbach, J. K., and Dierkhising, R. A. (2011) Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 141, 1249-1253
8. Braunlin, W., Zhorov, E., Guo, A., Apruzzese, W., Xu, Q., Hook, P., Smisek, D. L., Mandeville, W. H., and Holmes-Farley, S. R. (2002) Bile acid binding to sevelamer HCl. Kidney Int. 62, 611-619
9. Rastogi, A. (2013) Sevelamer revisited: pleiotropic effects on endothelial and cardiovascular risk factors in chronic kidney disease and end-stage renal disease. Ther. Adv. Cardiovasc. Dis. 7, 322-342
10. Staels, B., Handelsman, Y., and Fonseca, V. (2010) Bile acid sequestrants for lipid and glucose control. Curr. Diab. Rep. 10, 70-77
11. Kobayashi, M., Ikegami, H., Fujisawa, T., Nojima, K., Kawabata, Y., Noso, S., Babaya, N., Itoi-Babaya, M., Yamaji, K., Hiromine, Y., Shibata, M., and Ogihara, T. (2007) Prevention and treatment of obesity, insulin resistance, and diabetes by bile acid-binding resin. Diabetes 56, 239-247
12. Potthoff, M. J., Potts, A., He, T., Duarte, J. A., Taussig, R., Mangelsdorf, D. J., Kliewer, S. A., and Burgess, S. C. (2013) Colesevelam suppresses hepatic glycogenolysis by TGR5-mediated induction of GLP-1 action in DIO mice. Am. J. Physiol. Gastrointest. Liver Physiol. 304, G371- 80
13. Harach, T., Pols, T. W., Nomura, M., Maida, A., Watanabe, M., Auwerx, J., and Schoonjans, K. (2012) TGR5 potentiates GLP-1 secretion in response to anionic exchange resins. Sci. Rep. 2, 430
14. Taniai, M., Hashimoto, E., Tobari, M., Yatsuji, S., Haruta, I., Tokushige, K., and Shiratori, K. (2009) Treatment of nonalcoholic steatohepatitis with colestimide. Hepatol. Res. 39, 685-693
15. Thomas, C., Pellicciari, R., Pruzanski, M., Auwerx, J., and Schoonjans, K. (2008) Targeting bile-acid signalling for metabolic diseases. Nat. Rev. Drug Discov. 7, 678-693
16. Pols, T. W., Noriega, L. G., Nomura, M., Auwerx, J., and Schoonjans, K. (2011) The bile acid membrane receptor TGR5 as an emerging target in metabolism and inflammation. J. Hepatol. 54, 1263-1272
17. Kong, B., Luyendyk, J. P., Tawfik, O., and Guo, G. L. (2009) Farnesoid X receptor deficiency induces nonalcoholic steatohepatitis in low-density lipoprotein receptor-knockout mice fed a high-fat diet. J. Pharmacol. Exp. Ther. 328, 116-122
18. Cheng, Q., Inaba, Y., Lu, P., Xu, M., He, J., Zhao, Y., Guo, G. L., Kuruba, R., Vega, R. De, Evans, R. W., and Li, S. (2015) Chronic activation of FXR in transgenic mice caused perinatal toxicity and sensitized mice to cholesterol toxicity. Mol. Endocrinol. 29, 571-582
19. McMahan, R. H., Wang, X. X., Cheng, L. L., Krisko, T., Smith, M., El Kasmi, K., Pruzanski, M., Adorini, L., Golden-Mason, L., Levi, M., and Rosen, H. R. (2013) Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease. J. Biol. Chem. 288, 11761-11770
20. Jiang, C., Xie, C., Li, F., Zhang, L., Nichols, R. G., Krausz, K. W., Cai, J., Qi, Y., Fang, Z. Z., Takahashi, S., Tanaka, N., Desai, D., Amin, S. G., Albert, I., Patterson, A. D., and Gonzalez, F. J. (2015) Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J. Clin. Invest. 125, 386-402
21. Lanaspa, M. A., Ishimoto, T., Li, N., Cicerchi, C., Orlicky, D. J., Ruzycki, P., Ruzicky, P., Rivard, C., Inaba, S., Roncal-Jimenez, C. A., Bales, E. S., Diggle, C. P., Asipu, A., Petrash, J. M., Kosugi, T., et al. (2013) Endogenous fructose production and metabolism in the liver contributes to the development of metabolic syndrome. Nat. Commun. 4, 2434
22. Schmittgen, T. D., and Livak, K. J. (2008) Analyzing real-time PCR data by the comparative CT method. Nat. Protoc. 3, 1101-1108
23. Braunersreuther, V., Viviani, G. L., Mach, F., and Montecucco, F. (2012) Role of cytokines and chemokines in non-alcoholic fatty liver disease. World J. Gastroenterol. 18, 727-735
24. Lesmana, C. R., Hasan, I., Budihusodo, U., Gani, R. A., Krisnuhoni, E., Akbar, N., and Lesmana, L. A. (2009) Diagnostic value of a group of biochemical markers of liver fibrosis in patients with non-alcoholic steatohepatitis. J. Dig. Dis. 10, 201-206
25. Szabo, G., and Csak, T. (2012) Inflammasomes in liver diseases. J. Hepatol. 57, 642-654
26. Kanda, H., Tateya, S., Tamori, Y., Kotani, K., Hiasa, K., Kitazawa, R., Kitazawa, S., Miyachi, H., Maeda, S., Egashira, K., and Kasuga, M. (2006) MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance and hepatic steatosis in obesity. J. Clin. Invest. 116, 1494-1505
27. Mas, E., Danjoux, M., Garcia, V., Carpentier, S., Ségui, B., and Levade, T. (2009) IL-6 deficiency attenuates murine diet-induced non-alcoholic steatohepatitis. PLoS ONE 4, e7929
28. Iredale, J. P. (2007) Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J. Clin. Invest. 117, 539-548
29. Chiang, J. Y. (2009) Bile acids: regulation of synthesis. J. Lipid Res. 50, 1955-1966
30. Schulz, C., Gomez Perdiguero, E., Chorro, L., Szabo-Rogers, H., Cagnard, N., Kierdorf, K., Prinz, M., Wu, B., Jacobsen, S. E., Pollard, J. W., Frampton, J., Liu, K. J., and Geissmann, F. (2012) A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science 336, 86-90
31. Gomez Perdiguero, E., Klapproth, K., Schulz, C., Busch, K., Azzoni, E., Crozet, L., Garner, H., Trouillet, C., de Bruijn, M. F., Geissmann, F., and Rodewald, H. R. (2015) Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors. Nature 518, 547-551
32. Morinaga, H., Mayoral, R., Heinrichsdorff, J., Osborn, O., Franck, N., Hah, N., Walenta, E., Bandyopadhyay, G., Pessentheiner, A. R., Chi, T. J., Chung, H., Bogner-Strauss, J. G., Evans, R. M., Olefsky, J. M., and Oh, D. Y. (2015) Characterization of distinct subpopulations of hepatic macrophages in HFD/obese mice. Diabetes 64, 1120-1130
33. Clària, J. (2012) Natural killer cell recognition and killing of activated hepatic stellate cells. Gut 61, 792-793
34. Kotas, M. E., Lee, H.-Y., Gillum, M. P., Annicelli, C., Guigni, B. A., Shulman, G. I., and Medzhitov, R. (2011) Impact of CD1d deficiency on metabolism. PLoS ONE 6, e25478
35. Gaemers, I. C., Stallen, J. M., Kunne, C., Wallner, C., van Werven, J., Nederveen, A., and Lamers, W. H. (2011) Lipotoxicity and steatohepatitis in an overfed mouse model for non-alcoholic fatty liver disease. Biochim. Biophys. Acta 1812, 447- 458
36. Longato, L. (2013) Non-alcoholic fatty liver disease (NAFLD): a tale of fat and sugar? Fibrogenesis Tissue Repair 6, 14
37. Feldstein, A. E., Werneburg, N. W., Canbay, A., Guicciardi, M. E., Bronk, S. F., Rydzewski, R., Burgart, L. J., and Gores, G. J. (2004) Free fatty acids promote hepatic lipotoxicity by stimulating TNF-ô expression via a lysosomal pathway. Hepatology 40, 185-194
38. Takahashi, Y., Soejima, Y., and Fukusato, T. (2012) Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J. Gastroenterol. 18, 2300-2308
39. Anstee, Q. M., and Goldin, R. D. (2006) Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int. J. Exp. Pathol. 87, 1-16
40. Wan, J., Benkdane, M., Teixeira-Clerc, F., Bonnafous, S., Louvet, A., Lafdil, F., Pecker, F., Tran, A., Gual, P., Mallat, A., Lotersztajn, S., and Pavoine, C. (2014) M2 Kupffer cells promote M1 Kupffer cell apoptosis: a protective mechanism against alcoholic and nonalcoholic fatty liver disease. Hepatology 59, 130-142
41. Matsubara, T., Li, F., and Gonzalez, F. J. (2013) FXR signaling in the enterohepatic system. Mol. Cell. Endocrinol. 368, 17-29
42. Watanabe, M., Morimoto, K., Houten, S. M., Kaneko-Iwasaki, N., Sugizaki, T., Horai, Y., Mataki, C., Sato, H., Murahashi, K., Arita, E., Schoonjans, K., Suzuki, T., Itoh, H., and Auwerx, J. (2012) Bile acid binding resin improves metabolic control through the induction of energy expenditure. PLoS ONE 7, e38286
43. Kalaany, N. Y., and Mangelsdorf, D. J. (2006) LXRS and FXR: the yin and yang of cholesterol and fat metabolism. Annu. Rev. Physiol. 68, 159-191
44. Tuominen, I., and Beaven, S. W. (2015) Intestinal farnesoid X receptor puts a fresh coat of wax on fatty liver. Hepatology 62, 646-648
45. Yao, J., Zhou, C.-S., Ma, X., Fu, B.-Q., Tao, L.-S., Chen, M., and Xu, Y.-P. (2014) FXR agonist GW4064 alleviates endotoxin-induced hepatic inflammation by repressing macrophage activation. World J. Gastroenterol. 20, 14430-14441 Downloaded